EUVIMED · CrossrefZeitschrift
The Prostate
ISSN 0270-4137 · Wiley
Neueste Artikel
Non–Prostate Cancer‐Related Factors That Influence Serum Prostate‐Specific Antigen: A Narrative Review of 45 Non‐Malignant PSA Modifiers
Prostatic Enlargement in Acromegaly Despite Preserved Lower Urinary Tract Function: A Cross‐Sectional Comparative Study
Plasma Steroid Trajectories From Day‐of‐Surgery Baseline After Robot‐Assisted Radical Prostatectomy for Prostate Cancer
Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI‐RADS 3 Lesions: A Two‐Center Retrospective Study
Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis
Association Between Preoperative Membranous Urethral Length and Urinary Continence Recovery After Retzius Sparing Robotic Assisted Radical Prostatectomy: Results From a Retrospective Single‐Center Study
External Validation of the Martini‐Klinik Nomogram Predicting the Indication for Adjuvant Radiation Therapy According to EAU Guidelines Among Patients With High‐Risk Prostate Cancer After Radical Prostatectomy
Metabolomic Insights Into Saliva as a Non‐Invasive Surrogate for Serum to Enable Community‐Based Biomarker Investigation
Evidence‐Based Treatment Ladder for Chronic Prostatitis/Chronic Pelvic Pain
Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
A Comparative Study of the Global Burden of Prostate Cancer (1990–2021): Emphasis on the Disparities Between the United States and China
Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort
Simple Prostatectomy is an Effective Option for BPH Patients With Hypocontractile Bladders
LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway
PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy
Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity
Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways
Minimally Invasive Holmium Laser Enucleation of the Prostate (MiLEP) Vs. HoLEP: Retrospective Analysis of Perioperative Outcomes in a Propensity Score‐Matched Cohort
Oncological Outcomes After Robotic Salvage Radical Prostatectomy in Patients Primarily Treated With Focal Versus Radiation Therapy: A Junior ERUS/YAU Collaborative Study
Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
Valosin‐Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy
National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis of Global Data
Outcome of Subsequent Therapies After 177 Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis
PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy
Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients
Jahrgänge
2026 · 1592025 · 1982024 · 1752023 · 1882022 · 1872021 · 1682020 · 1552019 · 2062018 · 1602017 · 1752016 · 1612015 · 1922014 · 1662013 · 1862012 · 1912011 · 1852010 · 1822009 · 1852008 · 1862007 · 1852006 · 1792005 · 1762004 · 1822003 · 1462002 · 1452001 · 1922000 · 2551999 · 2371998 · 2411997 · 2571996 · 2471995 · 1071994 · 1181993 · 741992 · 1041991 · 701990 · 861989 · 881988 · 751987 · 80
EUVIMED